{"id":4137,"date":"2025-07-17T10:19:04","date_gmt":"2025-07-17T07:19:04","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4137"},"modified":"2025-07-17T10:19:06","modified_gmt":"2025-07-17T07:19:06","slug":"sarepta-to-lay-off-about-500-employees-after-duchenne-gene-therapy-setbacks","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/es\/sarepta-to-lay-off-about-500-employees-after-duchenne-gene-therapy-setbacks\/","title":{"rendered":"Sarepta despedir\u00e1 a unos 500 empleados tras los reveses de la terapia g\u00e9nica para la enfermedad de Duchenne"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Sarepta declar\u00f3 que la compa\u00f1\u00eda tiene la intenci\u00f3n de detener el desarrollo de varios medicamentos y despedir a aproximadamente 361 empleados. Para 2026, la empresa prev\u00e9 que ambas medidas combinadas supongan un ahorro anual de m\u00e1s de 1400 millones de d\u00f3lares.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cNo adaptarnos a los recientes fracasos pondr\u00eda en riesgo nuestra viabilidad a largo plazo como organizaci\u00f3n y reducir\u00eda la oportunidad de brindar el mayor beneficio al mayor n\u00famero de pacientes que viven con enfermedades raras\u201d, declar\u00f3 el director ejecutivo de Sarepta, Doug Ingram, en una conferencia telef\u00f3nica el mi\u00e9rcoles por la tarde.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Reestructuraci\u00f3n estrat\u00e9gica<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Una reducci\u00f3n de la fuerza laboral de 36%, que afectar\u00e1 a aproximadamente 500 empleados, y que se proyecta que generar\u00e1 aproximadamente 120 millones de d\u00f3lares en ahorros anuales en costos en efectivo en 2026<\/li>\n\n\n\n<li>Se espera que la repriorizaci\u00f3n del oleoducto genere aproximadamente 300 millones de d\u00f3lares en ahorros anuales en costos no relacionados con el personal a partir de 2026<\/li>\n\n\n\n<li>Se prev\u00e9 un ahorro de costos de m\u00e1s de 100 millones de d\u00f3lares hasta finales de 2025, neto de indemnizaciones por despido estimadas y cargos \u00fanicos por un total de entre 32 y 37 millones de d\u00f3lares.<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>Sarepta stated that company intends to halt development on a number of medicinal products and lay off about 36% of its employees. By 2026, the business anticipates that the two actions taken combined will save over $400 million annually. &#8220;Failure to adapt&#8221; to recent failures &#8220;would risk our long-term viability as an organization and decrease [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4140,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[61,65],"class_list":["post-4137","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-gene-therapy","tag-sarepta"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/4137","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/comments?post=4137"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/4137\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media\/4140"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media?parent=4137"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/categories?post=4137"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/tags?post=4137"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}